JP2003511347A - ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御 - Google Patents

ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御

Info

Publication number
JP2003511347A
JP2003511347A JP2000606302A JP2000606302A JP2003511347A JP 2003511347 A JP2003511347 A JP 2003511347A JP 2000606302 A JP2000606302 A JP 2000606302A JP 2000606302 A JP2000606302 A JP 2000606302A JP 2003511347 A JP2003511347 A JP 2003511347A
Authority
JP
Japan
Prior art keywords
nitric oxide
endothelial cell
oxide synthase
subject
cell nitric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000606302A
Other languages
English (en)
Japanese (ja)
Inventor
リアオ，ジェイムス・ケイ
ラオフス，ウルリヒ
エントレス，マティアス
モスコウィッズ，マイケル・エイ
Original Assignee
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド filed Critical ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド
Publication of JP2003511347A publication Critical patent/JP2003511347A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
JP2000606302A 1999-03-19 2000-03-17 ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御 Pending JP2003511347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27344599A 1999-03-19 1999-03-19
US09/273,445 1999-03-19
PCT/US2000/007221 WO2000056403A1 (fr) 1999-03-19 2000-03-17 Regulation positive de l'oxyde nitrique synthase des cellules endotheliales de type iii par des inhibiteurs de la hmg-coa reductase

Publications (1)

Publication Number Publication Date
JP2003511347A true JP2003511347A (ja) 2003-03-25

Family

ID=23043964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000606302A Pending JP2003511347A (ja) 1999-03-19 2000-03-17 ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御

Country Status (5)

Country Link
EP (1) EP1175246A4 (fr)
JP (1) JP2003511347A (fr)
AU (1) AU3760300A (fr)
CA (1) CA2368187A1 (fr)
WO (1) WO2000056403A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033287A1 (fr) * 2004-09-21 2006-03-30 Sankyo Company, Limited PRÉPARATION PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE ET DE LA GLUTATHIONE
JP2006117645A (ja) * 2004-09-21 2006-05-11 Sankyo Co Ltd ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
JP2009513509A (ja) * 2003-07-07 2009-04-02 ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング 肺疾患および心臓血管疾患の予防および治療用の吸入薬の製造のための極限環境細菌から得られたオスモライトの使用、ならびに活性薬剤成分としてオスモライトを含む吸入装置

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6239172B1 (en) 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US6425881B1 (en) 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
JP2002539257A (ja) 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド 薬剤の脳内生物学的利用率の増加
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1370210A4 (fr) * 2001-02-07 2004-08-18 Mclean Hospital Corp Hypocholesterolemiants utilises pour traiter les troubles psychologiques et cognitifs
DE10257360A1 (de) * 2002-12-09 2004-07-08 Fresenius Kabi Deutschland Gmbh Gastro-intestinal verabreichbare Formulierung und deren Verwendung
WO2004096276A1 (fr) 2003-04-28 2004-11-11 Sankyo Company, Limited Composition activant l'aptitude a consommer du sucre
EP1621210B1 (fr) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Activateur de la production d'adiponectine
EP3138566B1 (fr) 2003-11-17 2022-01-26 BioMarin Pharmaceutical Inc. Traitement de la phénylcétonurie avec de la bh4
EP1729761A4 (fr) * 2004-03-05 2008-09-03 Eisai Co Ltd Traitement de cadasil avec des inhibiteurs de la cholinesterase
EP2111863B1 (fr) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Combinaison du fasudil et bosentan pour le traitement de l'hypertension artérielle pulmonaire
WO2008036846A2 (fr) * 2006-09-22 2008-03-27 Braincells, Inc. Modulation induite par hmg-coa-réductase de la neurogenèse
JP2010531299A (ja) * 2007-06-25 2010-09-24 ニコックス エス エイ 肺動脈高血圧症の治療における一酸化窒素放出性スタチンの使用
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20200253976A1 (en) * 2017-09-28 2020-08-13 University Of Massachusetts Endothelial Facilitation in Neurodegerative Diseases by Cerebral Blood Flow Enhancement
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138008A1 (fr) 2019-04-17 2020-10-22 Compass Pathfinder Limited Procedes pour traiter les troubles neurocognitifs, la douleur chronique, et pour reduire l'inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513509A (ja) * 2003-07-07 2009-04-02 ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング 肺疾患および心臓血管疾患の予防および治療用の吸入薬の製造のための極限環境細菌から得られたオスモライトの使用、ならびに活性薬剤成分としてオスモライトを含む吸入装置
WO2006033287A1 (fr) * 2004-09-21 2006-03-30 Sankyo Company, Limited PRÉPARATION PHARMACEUTIQUE CONTENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE ET DE LA GLUTATHIONE
JP2006117645A (ja) * 2004-09-21 2006-05-11 Sankyo Co Ltd ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物

Also Published As

Publication number Publication date
EP1175246A4 (fr) 2004-12-15
CA2368187A1 (fr) 2000-09-28
AU3760300A (en) 2000-10-09
EP1175246A1 (fr) 2002-01-30
WO2000056403A1 (fr) 2000-09-28

Similar Documents

Publication Publication Date Title
JP2003511347A (ja) ＩＩＩ型内皮細胞一酸化窒素合成酵素のＨＭＧ−ＣｏＡ還元酵素阻害物質による上方制御
US6147109A (en) Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6180597B1 (en) Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (fr) Remise a niveau de la synthase dl'oxyde nitrique des cellules endotheliales de type iii par des agents venant disloquer l'organisation cytosquelettique de l'actine
CA2358400C (fr) Procedes de traitement d'etats associes a l'accumulation d'un excedent de matrice extracellulaire
US6696480B2 (en) Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US10195204B2 (en) Methods of treating hemoglobinopathies
EP1809742B1 (fr) Methodes de traitement des etats associes a l'accumulation excessive de matrice extracellulaire
EP1014980A1 (fr) Utilisation de nitroxydes dans le traitement de l'hypertension essentielle
JPH09500366A (ja) 固形腫瘍及び他の疾患の治療のための薬剤の治療効果を改良する方法
WO2009002533A1 (fr) Thérapies d'affection abdominale inflammatoire
KR20180004816A (ko) Th2-유도된 천식의 치료에 사용하기 위한 gata-3 저해제
JP2020520386A (ja) 急性虚血性脳卒中の処置のための方法及び医薬組成物
US20050038102A1 (en) Upregulation of type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
WO2002026231A1 (fr) Utilisation d'oxydes d'azote dans le traitement de troubles vasculaires chez un animal diabetique
JP4563587B2 (ja) エンドセリンのレベル低下剤
TW200920354A (en) Association between an anti-atherothrombotic compound and an angiotensin-converting enzyme inhibitor
EP1721608A2 (fr) Régulation positive de l'oxyde nitrique synthase de cellules endotheliales de type III par des inhibiteurs de la HMG-CoA reductase
JP2001058949A (ja) 抗ショック剤
Mitch Cardiovascular
VM et al. 12 NITRIC OXIDE MODULATES THE NEUROGENIC CONTROL OF BLOOD
Fraune et al. Articles in PresS. Am J Physiol Renal Physiol (July 11, 2012). doi: 10.1152/ajprenal. 00672.2011
AU2012200392A1 (en) Methods for treating conditions associated with the accumulation of excess extracellular matrix